Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages

  Gollard, Russell P ^a   Selco, Scott ^b  

^a Cancer and Blood Specialists of Nevada   (United States)

^b St Rose Dominican Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD3 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; FOLIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MULTIVITAMIN; MYELOPEROXIDASE; NELARABINE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ATAXIC GAIT; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CEREBROSPINAL FLUID; CERVICAL SPINAL CORD; DETERIORATION; DRUG MEGADOSE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MALE; MEDIASTINUM MASS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PERONEUS NERVE PARALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; REPEAT PROCEDURE; SPINAL CORD DISEASE; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; THORAX PAIN; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; FATALITY; INTRASPINAL DRUG ADMINISTRATION; MEDIASTINUM TUMOR; PATHOLOGY; QUADRIPLEGIA; SPINAL CORD;

6-MERCAPTOPURINE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; INJECTIONS, SPINAL; MALE; MEDIASTINAL NEOPLASMS; METHOTREXATE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUADRIPLEGIA; SPINAL CORD; SPINAL CORD DISEASES;

EID: 84883099800     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.4728     Document Type: Article

References (15)

1. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood 85:2025-2037, 1995
2. Kantarjian HM, O'Brien S, Smith TL, et al: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547-561, 2000
3. DeAngelo DJ, Yu D, Johnson JL, et al: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136-5142, 2007
4. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007
5. Ferrell AS, Tubbs RS, Acakpo-Satchivi L, et al: Legacy and current understanding of the often-misunderstood Foix-Alajouanine syndrome: Historical vignette. J Neurosurg 111:902-906, 2009
6. Papayannidis C, Iacobucci I, Abbenante MC, et al: Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol 85:608, 2010
7. Kurtzberg J, Ernst TJ, Keating MJ, et al: Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23:3396-3403, 2005
8. Buie LW, Epstein SS, Lindley CM: Nelarabine: A novel purine antimetabolite antineoplastic agent. Clin Ther 29:1887-1899, 2007
9. Barth A, Newell DW, Nguyen LB, et al: Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res 762:79-88, 1997
10. Cherry CL, McArthur JC, Hoy JF, et al: Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 26:195-207, 2003
11. Rane K, Karlsten R, Sollevi A, et al: Spinal cord morphology after chronic intrathecal administration of adenosine in the rat. Acta Anaesthesiol Scand 43:1035-1040, 1999
12. Long-Boyle J, Huang J, Rydholm N, et al: Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol 51:679-686, 2011
13. Johnston DL, Bains T, Mandel K, et al: Fatal neurotoxicity in a patient with Down syndrome treated with chemotherapy, irradiation, stem cell transplant, and clofarabine. J Pediatr Hemat Oncol 32:e111-e113, 2010
14. Korycka A, Lech-Marańda E, Robak T: Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 3:123-136, 2008
15. Gandhi V, Plunkett W: Clofarabine and nelarabine: Two new purine nucleoside analogs. Curr Opin Oncol 18:584-590, 2006